Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...